Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Sunday, December 31, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2023 (2023-12-31): -369.71%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-427.48%
RETURN ON EQUITY (ROE) AVG 3Y
-170.94%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Clene Inc.
Market Cap
$49.96M
Return on Equity (ROE)
N/A
TTM Avg
-427.48%
3Y Avg
-170.94%
5Y Avg
N/A
Market Cap
$50.25M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$49.50M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
Market Cap
$50.51M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
Market Cap
$49.40M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$51.12M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$51.23M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
Market Cap
$51.58M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
Market Cap
$52.95M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.96M | N/A | -427.48% | -170.94% | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -708.48% | 156.13% | 510.26% | 342.91% |
| Celularity Inc. (CELU)vs › | $49.50M | N/A | -206.96% | -221.50% | -349.91% |
| Apollomics, Inc. (APLM)vs › | $50.51M | N/A | -382.07% | -282.25% | -171.00% |
| biote Corp. (BTMD)vs › | $49.40M | N/A | -24.59% | -14.57% | 93.61% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | -52.72% | -32.48% | -92.81% | -85.98% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | -278.89% | -162.92% | 25.71% | 0.37% |
| INmune Bio, Inc. (INMB)vs › | $51.58M | -90.44% | -163.19% | -112.62% | -86.58% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | N/A | 31.64% | 119.26% | -26.51% |
| ImageneBio Inc (IMA)vs › | $53.01M | -36.94% | -31.55% | -37.51% | -20.44% |
ROE
N/A
ROA
-171.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-12-31 | -369.71% |
| 2023-09-30 | -188.66% |
| 2023-06-30 | -227.29% |
| 2022-12-31 | -924.25% |
| 2022-03-31 | 826.08% |
| 2021-12-31 | -77.32% |
| 2021-09-30 | -235.40% |
| 2020-09-30 | -53.37% |
| 2019-12-31 | -149.44% |
